New Evidence With BTK Inhibitor Therapy in CLL and MCL From EHA 2022

In this episode, Othman Al-Sawaf, MD, and Lydia Scarfò, MD, discuss key trials presented at EHA 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: GAIA/CLL13: phase III trial of time-limited venetoclax + obinutuzumab ± ibrutinib vs chemoimmunotherapy as first-line therapy for CLLFLAIR: randomized, adaptive-design phase III trial with data reported from ibrutinib + venetoclax and ibrutinib arm; includes measurable residual disease–defined therapy durationBRUIN: phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)SHINE: phase III study of ibrutinib with bendamustine + rituximab and rituximab maintenance in older patients with MCLPresenters:Othman Al-Sawaf, MDFaculty of MedicineUniversity Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, GermanyVisiting ScientistThe Francis Crick InstituteUCL Cancer Institute, University College London London, United KingdomLydia Scarfò, MDLaboratory of B-Cell Neoplasia, Division of Experimental OncologyStrategic Research Program on CLLUniversità Vita Salute San Raffaele and IRCCS Ospedale San RaffaeleMilano, ItalyLink to full program:https://bit.ly/3OQ6634 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.